ALIM - Alimera Sciences, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.992
-0.008 (-0.80%)
As of 10:03AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.000
Open0.99
Bid0.970 x 3000
Ask0.992 x 800
Day's Range0.973 - 0.992
52 Week Range0.740 - 1.380
Volume788
Avg. Volume106,707
Market Cap69.518M
Beta (3Y Monthly)0.48
PE Ratio (TTM)5.33
EPS (TTM)0.186
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    Alimera Sciences to Present at Upcoming Investor Conferences

    ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced ...

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT

    Q3 2018 Alimera Sciences Inc Earnings Call

  • Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates
    Zacks9 days ago

    Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates

    Alimera Sciences (ALIM) delivered earnings and revenue surprises of 16.67% and 0.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 days ago

    Alimera Sciences: 3Q Earnings Snapshot

    The Alpharetta, Georgia-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring gains, were 5 cents per share. The results beat Wall Street expectations. The average ...

  • ACCESSWIRE10 days ago

    Alimera Sciences Reports Third Quarter 2018 Results

    Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November ...

  • ACCESSWIRE23 days ago

    Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

    ATLANTA, GA / ACCESSWIRE / October 23, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced ...

  • ACCESSWIRE24 days ago

    Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology

    ATLANTA, GA / ACCESSWIRE / October 22, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that six posters on ILUVIEN® will be available during the 2018 Annual Meeting of the American Academy of Ophthalmology (AAO) at McCormick Place in Chicago, October 26-30. In addition, Alimera is sponsoring an educational event at the meeting. "We continue to generate exciting data on ILUVIEN, including two posters from our ongoing prospective PALADIN study," said Dan Myers, CEO of Alimera.

  • Simply Wall St.last month

    How Alimera Sciences Inc (NASDAQ:ALIM) Can Impact Your Portfolio Volatility

    Anyone researching Alimera Sciences Inc (NASDAQ:ALIM) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...

  • Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
    PR Newswire2 months ago

    Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

    "CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the Treatment of Persistent or Recurrent DME" Symposium to be held on Friday ATLANTA , Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ...

  • Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting
    PR Newswire2 months ago

    Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

    ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the 2018 Annual Meeting of the Retina Society being held September 12-15 at The Palace Hotel in San Francisco. "We are pleased with the presentations and poster being shared this year at Retina Society," said Dan Myers, CEO of Alimera. "We are particularly excited to share new data from the USER (U.S. Retrospective Chart Review in Patients Receiving ILUVIEN) Study in one of the presentations that we believe is relevant in the management of DME.

  • Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock
    PR Newswire2 months ago

    Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

    ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (Deerfield) to exchange the Alimera Series B Convertible Preferred Stock previously held by Deerfield (the Series B) for newly issued Alimera Series C Convertible Preferred Stock (the Series C). Deerfield is exchanging all 8,416 shares of the Series B it purchased in December 2014 for 10,150 newly issued shares of the Series C. "In the past, we believe the significance of the Series B liquidation preference, notwithstanding the limited circumstances in which the holders might have received it, negatively affected the value attributable to our common shareholders.

  • Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference
    PR Newswire3 months ago

    Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

    ATLANTA , Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, ...

  • Alimera Sciences to Present at the Annual B. Riley Healthcare Conference
    PR Newswire3 months ago

    Alimera Sciences to Present at the Annual B. Riley Healthcare Conference

    ATLANTA , Aug. 28, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, ...

  • Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?

    Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ALIM earnings conference call or presentation 31-Jul-18 1:00pm GMT

    Q2 2018 Alimera Sciences Inc Earnings Call

  • ACCESSWIRE4 months ago

    Alimera Sciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 9:00 AM Eastern Time. ...

  • Associated Press4 months ago

    Alimera Sciences: 2Q Earnings Snapshot

    On a per-share basis, the Alpharetta, Georgia-based company said it had a loss of 6 cents. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Alimera Sciences Reports Second Quarter 2018 Results
    PR Newswire4 months ago

    Alimera Sciences Reports Second Quarter 2018 Results

    - Record Net Revenue of $10.9 Million in Q2 2018 - Record U.S. End User Demand in Q2 2018 ATLANTA , July 30, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical ...

  • Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018
    PR Newswire4 months ago

    Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

    ATLANTA , July 18, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release ...

  • Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting
    PR Newswire4 months ago

    Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

    ATLANTA , July 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ...

  • InvestorPlace4 months ago

    Alimera Stock Grew 25 Percent and It Is Just Getting Warmed Up

    With that said, what drove Alimera stock higher last week? On May 31, Alimera announced that the Spanish Ministry of Health approved the pricing and reimbursement of ILUVIEN, a drug that treats patients suffering from vision issues related to chronic diabetic macular edema (DME). The full reimbursement in the region should drive revenue growth higher in the quarters ahead.

  • Benzinga5 months ago

    B. Riley FBR: 3 Reasons To Buy Alimera Sciences

    Nano-cap pharma company  Alimera Sciences Inc (NASDAQ: ALIM ) could nearly triple in value for three key reasons, according to B. Riley FBR.  The Analyst Analyst Andrew D'Silva initiated coverage of Alimera ...

  • When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit?
    Simply Wall St.5 months ago

    When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit?

    Alimera Sciences Inc’s (NASDAQ:ALIM): Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. With the latestRead More...

  • Alimera Sciences Appoints Mary T. Szela to its Board of Directors
    PR Newswire5 months ago

    Alimera Sciences Appoints Mary T. Szela to its Board of Directors

    ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors.  Ms. Szela is currently the Chief Executive Officer and President of Surefire Medical Inc., which develops infusion technologies for cancer care. Ms. Szela brings extensive medical management and leadership experience to Alimera's Board. Prior to joining Surefire Medical as its CEO and President, Ms. Szela served as CEO of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics.  Prior to Novelion, she was CEO of Melinta Therapeutics.  Ms. Szela held ascending management positions at Abbott Laboratories, including President of the company's $8 billion U.S. pharmaceutical business.  She developed global brands such as Humira® and served as Vice President for global strategic marketing and services.

  • The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability
    PR Newswire5 months ago

    The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

    ATLANTA, June 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom (UK) National Institute for Health and Care Excellence (NICE) will undertake a partial review and appraisal of Technology Assessment 301. Currently reimbursement of ILUVIEN in England and Wales is only available for patients who have had their natural lens replaced with an artificial one (termed "pseudophakic").